RNA sequencing reveals insight into tuberculosis infection
Using single-cell RNA sequencing, researchers have shown that interferon response is correlated with tuberculosis progression.
List view / Grid view
Using single-cell RNA sequencing, researchers have shown that interferon response is correlated with tuberculosis progression.
A study has shown that targeting the protein Nsp1 can inhibit genes for viral replication, which could lead to new COVID-19 treatments.
A new vaccine is effective at preventing opioid overdose from fentanyl and carfentanil in rodents, according to a new study.
Comparing the original SARS-CoV-2 Spike protein with a mutated version, researchers have potentially revealed why the mutated version is dominant.
A key process in β-cell regeneration has been discovered by researchers who say this could lead to improved treatments for diabetes.
A team has revealed that viruses ‘hijack’ a molecular process in the cell, inhibiting the body’s response to viral infection.
A team has developed a machine learning approach to screen for and identify drugs that could be repurposed against COVID-19 in the elderly.
Using NMR spectroscopy, researchers have partially observed the structure of heat shock proteins that bind to proteins that cause Huntington's disease.
A study has shown that inhibiting the enzyme PRMT5 can suppress the growth of glioblastoma cells in pre-clinical studies.
Researchers have synthesised peptides that function like a soluble chemokine receptor, blocking atherosclerosis in animal models.
An enzyme in fruit fly larvae plays a role in reactivating neural stem cells, which could explain how some neurodevelopmental disorders occur.
Research has shown that ACE2 and several integrins containing SLiMs are involved in SARS-CoV-2 infection, presenting new therapeutic targets.
A team has shown that STING activation is a new molecular target in the fight against graft-versus-host disease (GVHD).
A study has used artificial intelligence to reveal adeno-associated virus (AAV) capsid variants for use in gene therapies.
Researchers have shown that a GLP-1/GIP dual-agonist targets the GIP receptor in the brain and CNS to reduce body weight and food intake.